Kaizuka T, Kurihara R, Harumiya M, Kimura T, et al. Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation. J Dermatol 2023 Mar 8. doi: 10.1111/1346-8138.16759.
PMID: 36890675